Visual Hallucinations in Dementia With Lewy Bodies

Visual Hallucinations in Dementia With Lewy Bodies

Overview

Visual hallucinations (VH) are a core clinical feature of [Dementia With Lewy Bodies](/diseases/dementia-with-lewy-bodies) (DLB), occurring in approximately 60-90% of patients and representing one of the most distinctive neuropsychiatric manifestations of the synucleinopathies[@mckeith2020]. Unlike the visual distortions seen in other dementias, DLB-associated VH are characteristically well-formed, detailed, and often feature people, animals, or objects that are experienced with full conviction and emotional engagement[@walker2015].

The neurobiology of VH in DLB is multi-factorial, arising from the convergence of cholinergic dysfunction, visual processing impairment, attentional dysregulation, and brainstem pathology that disrupts the normal gating of visual perception. Critically, visual symptoms — including VH and milder visual disturbances — often manifest years before the onset of dementia, making them critical prodromal markers for early DLB identification[@erdal2023][@donaghy2022].

Pathophysiological Framework

The Attention-Perception Model

The leading cognitive model for VH in DLB is the attention-perception (A-P) framework, which proposes that VH arise from a failure of visual perception due to impaired bottom-up visual processing combined with compensatory over-recruitment of top-down attention[@collerton2005][@morroroberts2020]. In this model:

Visual Hallucinations in Dementia With Lewy Bodies

Overview

Visual hallucinations (VH) are a core clinical feature of [Dementia With Lewy Bodies](/diseases/dementia-with-lewy-bodies) (DLB), occurring in approximately 60-90% of patients and representing one of the most distinctive neuropsychiatric manifestations of the synucleinopathies[@mckeith2020]. Unlike the visual distortions seen in other dementias, DLB-associated VH are characteristically well-formed, detailed, and often feature people, animals, or objects that are experienced with full conviction and emotional engagement[@walker2015].

The neurobiology of VH in DLB is multi-factorial, arising from the convergence of cholinergic dysfunction, visual processing impairment, attentional dysregulation, and brainstem pathology that disrupts the normal gating of visual perception. Critically, visual symptoms — including VH and milder visual disturbances — often manifest years before the onset of dementia, making them critical prodromal markers for early DLB identification[@erdal2023][@donaghy2022].

Pathophysiological Framework

The Attention-Perception Model

The leading cognitive model for VH in DLB is the attention-perception (A-P) framework, which proposes that VH arise from a failure of visual perception due to impaired bottom-up visual processing combined with compensatory over-recruitment of top-down attention[@collerton2005][@morroroberts2020]. In this model:

Cortical and Subcortical Contributions

VH in DLB involve dysfunction across multiple interconnected regions[@ffytche2017]:

| Region | Pathology Type | Contribution to VH |
|--------|---------------|-------------------|
| Primary visual cortex (V1) | Alpha-synuclein, reduced activity | Reduced sensory input, "noise" in visual stream |
| Inferotemporal cortex | Tau, alpha-synuclein | Impairs object recognition and categorization |
| Ventral visual stream | Alpha-synuclein | Disrupts form and face processing |
| Dorsal visual stream | Lewy body inclusions | Impairs spatial localization of objects |
| Superior colliculus | Alpha-synuclein, cell loss | Fails to suppress competing stimuli |
| Pedunculopontine nucleus (PPN) | Cholinergic neuron loss | Loss of cortical arousal and sensory gating |
| Locus coeruleus | Noradrenergic neuron loss | Impaired attention and salience assignment |
| Nucleus basalis of Meynert | Cholinergic neuron loss | Reduced cortical activation for sensory processing |
| Retina | Alpha-synuclein, RNFL thinning | Direct visual pathway impairment |

Cholinergic Dysfunction

The cholinergic system plays a central role in VH pathogenesis in DLB. Cholinergic deficits are among the most severe of any neurodegenerative condition, exceeding even Alzheimer's disease in some regions[@dott2021].

Nucleus Basalis of Meynert (NbM)

The NbM provides the primary cholinergic innervation to the neocortex. In DLB:

• Severe loss of NbM neurons (up to 70-90% in some cohorts)
• Cholinergic deficits correlate with VH severity
• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are the primary treatment for VH in DLB
• Cholinesterase inhibitors reduce VH frequency and severity by 30-50% in controlled trials[@serotaz2023]

Pedunculopontine Nucleus (PPN)

The PPN is the major cholinergic nucleus of the brainstem reticular activating system. PPN degeneration in DLB:

• Disrupts cortical arousal and wakefulness
• Impairs sensory gating at the thalamic level
• Contributes to REM sleep behavior disorder (RBD), which shares a common pathophysiology with VH
• Deep brain stimulation of the PPN has been explored to reduce VH in PD/DLB[@dott2021]

Visual Cortex Cholinergic Innervation

Cholinergic inputs to the visual cortex (from NbM) modulate:

• Signal-to-noise ratio in visual processing
• Attention-driven modulation of sensory coding
• Top-down attentional selection

Prodromal Visual Disturbances

Visual symptoms in DLB often precede frank VH by years, providing a window for early identification[@erdal2023][@donaghy2022]:

Early Prodromal Features

Progression to VH

The prodromal phase typically evolves through:

Prodromal DLB Diagnostic Criteria

The 2020 DLB consensus criteria recognize visual symptoms as part of the prodromal DLB category:

• Fluctuating cognition with pronounced variations in attention and alertness
• Recurrent visual hallucinations that are typically well-formed and detailed
• Spontaneous parkinsonism (may not be present in prodromal)
• REM sleep behavior disorder (RBD) (most specific prodromal marker)[@mckeith2020]

Charles Bonnet Syndrome Overlap

Charles Bonnet Syndrome (CBS) — complex visual hallucinations in visually impaired individuals — shares significant mechanistic overlap with VH in DLB, providing important insights into the underlying neurobiology[@kumar2025].

Shared Mechanisms

| Feature | CBS | DLB VH |
|---------|-----|--------|
| Primary cause | Visual deprivation (peripheral) | Neurodegeneration (central) |
| Hallucination content | Similar (people, animals, patterns) | Similar |
| Insight | Often preserved | Often preserved early |
| Cholinergic involvement | Unclear | Central role |
| Predictive coding | Over-recruitment of predictions | Over-recruitment of predictions |
| Brainstem gating | May be intact | Impaired |

Key Insight: The Predictive Brain

Both CBS and DLB VH support the view that visual perception is fundamentally predictive — the brain constantly generates predictions about the visual world and compares them against incoming sensory data. When sensory input is reduced (due to eye disease in CBS) or degraded (due to neurodegeneration in DLB), predictions are less constrained by reality and can break through into conscious awareness as hallucinations.

The critical difference between CBS and DLB VH is:

• CBS: The sensory input is reduced but the gating mechanism remains intact — hallucinations occur when predictions are not adequately constrained
• DLB: The gating mechanism itself is impaired (brainstem pathology) in addition to degraded sensory input — this dual insult makes VH more frequent, more florid, and harder to treat

Clinical Implications

• Patients with DLB and preserved vision can still develop VH due to central mechanisms
• Conversely, visually impaired patients who develop VH should be screened for early DLB
• The CBS-DLB overlap suggests that enhancing bottom-up sensory input (e.g., optimizing eyeglass prescriptions, improving lighting) may reduce VH in both conditions[@kumar2025]

REM Sleep Behavior Disorder Connection

REM sleep behavior disorder (RBD) is the single most specific prodromal marker for DLB, and shares a common pathophysiological basis with VH[@surak2022][@donaghy2022].

Shared Brainstem Vulnerability

Both RBD and VH arise from the same brainstem nuclei that degenerate early in the synucleinopathies:

• Sublaterodorsal nucleus (SLD): Key for REM sleep atonia. Degeneration causes RBD (loss of muscle paralysis during REM)
• Pedunculopontine nucleus (PPN): Key for REM sleep arousal and sensory gating. Degeneration contributes to VH
• Locus coeruleus (LC): Noradrenergic nucleus. Degeneration affects both REM regulation and attention
• Raphe nuclei: Serotonergic nuclei. Contributes to both sleep-wake regulation and mood

Clinical Correlation

• Over 80% of DLB patients have RBD at some point in their disease
• RBD precedes VH in the majority of cases by months to years
• The presence of RBD in a patient with cognitive symptoms strongly predicts eventual DLB (rather than AD)
• Patients with RBD who develop VH show more aggressive disease progression

Therapeutic Implications

• Treating RBD (e.g., clonazepam, melatonin) does not directly address VH
• Cholinesterase inhibitors treat VH but not RBD
• A unified treatment targeting both brainstem nuclei could address both symptoms
• PPN deep brain stimulation is under investigation for combined RBD/VH treatment[@dott2021]

Retinal Biomarkers

The retina provides a unique window into DLB pathology, as it is the only part of the CNS directly observable in vivo. Retinal changes in DLB serve as biomarkers for VH and disease progression[@chen2024][@rombos2024].

Optical Coherence Tomography (OCT) Findings

| Finding | Significance for VH |
|---------|---------------------|
| Peripapillary RNFL thinning | Global cholinergic degeneration; correlates with VH severity |
| Ganglion cell-inner plexiform layer (GCIPL) thinning | Specific to inner retinal layers affected by alpha-synuclein |
| Macular ganglion cell loss | Predicts VH occurrence and severity |
| Foveal thinning | Visual acuity impairment in DLB |
| Reduced macular vessel density | Microvascular dysfunction in DLB |

Alpha-Synuclein in the Retina

• Alpha-synuclein aggregates have been detected in the retina of DLB and PD patients post-mortem
• Retinal alpha-synuclein correlates with cortical alpha-synuclein burden
• Retinal imaging may serve as a proxy for brain alpha-synuclein pathology
• Seed amplification assays are being developed for retinal tissue and fluid[@chen2024]

Retinal Biomarker Correlation with VH

• Greater RNFL thinning correlates with more frequent and severe VH
• Macular GCIPL loss specifically predicts VH occurrence
• Retinal microvascular changes may precede clinical VH
• Retinal OCT is being evaluated as a tool to identify prodromal DLB patients who will develop VH[@rombos2024]

Biomarker Integration

Retinal biomarkers complement other DLB markers:

| Biomarker Modality | Measure | VH Relevance |
|-------------------|---------|--------------|
| Retinal OCT | RNFL, GCIPL thickness | Structural correlates of VH severity |
| CSF alpha-synuclein RT-QuIC | Seed amplification | Reflects synuclein burden, predicts VH |
| CSF NfL | Neurofilament light chain | General neurodegeneration, correlates with VH |
| DaTSCAN/SPECT | Dopamine transporter imaging | Supports DLB diagnosis, indirect VH relevance |
| FDG-PET | Glucose metabolism | Visual cortex hypometabolism in VH |

Clinical Features of VH in DLB

Phenomenology

Content: DLB VH are characteristically well-formed and detailed:

• People: Often children, strangers, or deceased relatives
• Animals: Dogs, cats, birds — frequently seen in familiar settings
• Objects: Furniture, flowers, vehicles
• Scenes: Complex vignettes with multiple elements

• Often occur in low-stimulation environments (evening, unfamiliar settings)
• Can be triggered by pattern and texture (e.g., carpets, curtains — pareidolias)
• May persist for minutes to hours
• Patients may interact with hallucinations (talking, gesturing)

• Early DLB: often retain insight (patient recognizes VH as unreal)
• Advanced DLB: progressively lose insight, become fully convinced
• Fluctuating insight is characteristic

Cognitive Profile

Patients with VH in DLB typically show:

• Relative preservation of episodic memory (compared to AD)
• Severe deficits in attention and executive function
• Profound visual processing impairment (object recognition, spatial processing)
• Fluctuating cognition — periods of clear awareness alternate with confusion

Differential Diagnosis

VH in DLB must be distinguished from:

• AD hallucinations: Typically simpler, more fragmentary; occur later in disease
• Parkinson's disease VH: Similar phenomenology; often harder to treat
• Delirium: Acute onset, fluctuating, impaired consciousness
• Charles Bonnet syndrome: Preserved cognition, clear visual deficit
• Peduncular hallucinosis: Brainstem lesions (vascular, neoplastic) — distinct etiology

Treatment Approaches

Pharmacological

| Treatment | Mechanism | Efficacy for VH |
|-----------|-----------|----------------|
| Rivastigmine | Cholinesterase inhibitor | Strong evidence — reduces VH frequency and severity; only FDA-approved for PD dementia |
| Donepezil | Cholinesterase inhibitor | Moderate evidence; widely used off-label |
| Galantamine | Cholinesterase inhibitor | Some evidence; also has nicotinic effects |
| Quetiapine | Atypical antipsychotic | Limited evidence; risk of cerebrovascular events |
| Pimavanserin | 5-HT2A inverse agonist | FDA-approved for PD psychosis; emerging DLB data |
| Clonazepam | Benzodiazepine | For RBD, not VH |
| Melatonin | Hormone | For RBD, minimal VH effect |

Key principle: Antipsychotics (typical and many atypical) should be AVOIDED in DLB due to severe neuroleptic sensitivity — risk of fatal parkinsonism exacerbation.

Non-Pharmacological

• Optimize sensory input: Ensure adequate spectacle correction, proper lighting, hearing aids
• Environmental modifications: Reduce shadows, increase contrast, reduce mirrors
• Validate and redirect: Do not argue about hallucinations; acknowledge and gently redirect
• Caregiver education: Understanding VH reduces caregiver distress and improves patient outcomes
• Reality orientation: Clocks, calendars, photographs in view
• Activity engagement: Structured activities reduce空闲 time when VH occur

Research Challenges and Open Questions

See Also

• [Dementia With Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein and Synucleinopathies](/mechanisms/alpha-synuclein)
• [Cholinergic Dysfunction in Neurodegeneration](/mechanisms/acetylcholine-signaling-neurodegeneration)
• [REM Sleep Behavior Disorder](/mechanisms/rem-sleep-behavior-disorder)
• [Retinal Biomarkers in Neurodegeneration](/mechanisms/retinal-biomarkers-neurodegeneration)
• [Neuropsychiatric Symptoms in Neurodegeneration](/mechanisms/neuropsychiatric-symptoms)
• [Pedunculopontine Nucleus](/brain-regions/pedunculopontine-nucleus)
• [Nucleus Basalis of Meynert](/entities/nucleus-basalis-meynert)

Pathway Diagram

The following diagram shows the key molecular relationships involving Visual Hallucinations in Dementia With Lewy Bodies discovered through SciDEX knowledge graph analysis: